Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PROCEPT BioRobotics Corporation filings document the public-company disclosures of a Nasdaq-listed surgical robotics business focused on urology. Recent Form 8-K reports furnish quarterly financial results, revenue and operating commentary, investor presentation materials, and updates tied to the company’s AQUABEAM and HYDROS Robotic Systems, Aquablation therapy, and related product and clinical programs.
Proxy and governance filings cover board composition, committee assignments, director independence, executive compensation, equity awards, and severance or change-of-control arrangements. The filings also identify PRCT common stock registered under Section 12(b) and traded on The Nasdaq Global Market.
PROCEPT BioRobotics EVP and CFO Kevin Waters reported a small sale of 357 shares of common stock. The shares were sold on June 8, 2026 at an average price of $28.479 per share. According to the filing, the sale was made through the company’s sell-to-cover process to satisfy tax withholding obligations tied to Restricted Stock Units that vested on June 5, 2026. After this transaction, Waters directly owns 151,201 shares, indicating the sale was minor relative to his overall holdings.
PROCEPT BioRobotics EVP and CTO Barry L. Templin reported a small sale of 358 shares of Common Stock on June 8, 2026 at $28.479 per share. According to the footnotes, this transaction was executed under the company’s sell-to-cover process to satisfy tax withholding obligations related to Restricted Stock Units that vested on June 5, 2026, indicating it was a routine tax-driven event rather than a discretionary sale. After this transaction, Templin directly holds 68,953 shares of PROCEPT BioRobotics common stock. The footnotes also note that his holdings include 860 shares acquired on May 14, 2026 through the company’s 2021 Employee Stock Purchase Plan.
The issuer notice reports a proposed sale of 285 shares of common stock under a Form 144. The filing lists a Restricted Stock Vesting event dated 06/05/2026 and a filing/processing date of 06/08/2026. The transaction is described as compensation-related and lists an issuer and broker reference.
PRCT submitted a Rule 144 notice regarding the proposed sale of 357 shares of Common Stock that vested on 06/05/2026. The filing lists a trade/filing date of 06/08/2026 and a reported value of $10,167.00 associated with those shares.
The filing also records prior activity by Kevin Waters: a sale of 706 shares on 03/17/2026 with an aggregate figure of $19,876.16. The securities are listed for NASDAQ under CUSIP 56918844.
PRCT reported an insider sale notice for previously restricted common stock. The filing lists 358 shares designated "Securities To Be Sold" tied to Restricted Stock Vesting with an effective date of 06/05/2026. It also records 882 shares sold on 03/17/2026 by Barry L. Templin.
AllianceBernstein L.P. amended its Schedule 13G to report 147,327 shares of PROCEPT BioRobotics Corp Common Stock held in discretionary client accounts. The filing states AllianceBernstein has sole voting power for 146,027 shares and sole dispositive power for 147,327 shares, representing 0.3% of the class. The amendment is signed on 05/15/2026.
PROCEPT BioRobotics Corp executive Barry L. Templin, EVP and Chief Technology Officer, filed an initial ownership report showing his equity stake in the company. The filing lists 69,311 shares of Common Stock held directly and 56,457 shares held indirectly through the Templin Trust.
It also details several stock options to buy Common Stock, including 29,615 underlying shares at an exercise price of $25.35 per share expiring in 2036 and 34,591 underlying shares at $5.18 per share expiring in 2030. Footnotes describe these as time‑vested grants with monthly vesting schedules tied to continued service.
PROCEPT BioRobotics reported first-quarter 2026 revenue of $83.1 million, up 20% from $69.2 million a year earlier, driven by higher system sales, consumables, and service, mainly in the United States.
Gross margin improved slightly to 65%, but the company’s net loss widened to $31.6 million, reflecting increased research, sales, and administrative spending to support growth. Operating cash outflow was $38.1 million, and cash and cash equivalents totaled $245.6 million with $52.0 million of term debt outstanding. The global installed base reached 971 robotic systems, including 765 in the U.S.
PROCEPT BioRobotics Corp ownership disclosure: Vanguard Capital Management reports beneficial ownership of 2,820,430 shares of common stock, representing 5% of the class. The filing states Vanguard has sole dispositive power over 2,820,430 shares and sole voting power over 421,363 shares. The filing notes these holdings include securities held for Vanguard funds and managed accounts.
PROCEPT BioRobotics reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose 20% year over year to $83.1 million, driven by higher U.S. system and handpiece sales and 25% growth in international revenue. Gross margin improved to 65%, up from 64% a year ago and 61% in the prior quarter.
U.S. Aquablation procedures reached about 12,200, up roughly 30% year over year, and the U.S. install base grew to 765 systems, a 40% increase. Despite this growth, operating expenses increased to $86.6 million, leading to a net loss of $31.6 million and Adjusted EBITDA loss of $18.1 million. The company ended the quarter with about $249 million in cash and reaffirmed 2026 guidance, including revenue of $390–$410 million and an Adjusted EBITDA loss of $30–$17 million. PROCEPT also highlighted recent FDA clearance of its second-generation FirstAssist AI software, further enhancing its HYDROS robotic system.